ArticleFrontiers in oncology2024

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.

Igor V Samoylenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.